AMBASSADOR trial finds adjuvant pembrolizumab extends disease-free survival in high-risk bladder cancer — not yet FDA-approved for this use

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

The NCI-sponsored, phase 3 AMBASSADOR trial (Alliance A031501, ClinicalTrials.gov NCT03244384; primary publication DOI 10.1056/NEJMoa2401726) found that adjuvant pembrolizumab significantly extended disease-free survival compared with observation alone in adults with high-risk muscle-invasive or locally advanced urothelial (bladder) carcinoma following surgical removal of the bladder. The trial randomized 702 patients 1:1 to pembrolizumab (200 mg every 3 weeks for up to one year) or observation. Pembrolizumab does NOT currently hold FDA approval for this specific adjuvant indication — a different, related PD-1 inhibitor, nivolumab, received FDA approval for adjuvant muscle-invasive urothelial carcinoma in 2021, and AMBASSADOR’s own enrollment was closed early specifically because of that competing approval. Overall survival, the trial’s co-primary endpoint, was not yet statistically significant at the reported follow-up and remains an immature endpoint.

What This Means

In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma. This is a real, positive trial result — but pembrolizumab has NOT been granted FDA approval for this specific adjuvant indication. A different, related PD-1 inhibitor, nivolumab, already holds that FDA approval (since 2021) for a similar adjuvant urothelial-carcinoma setting, and AMBASSADOR's own enrollment was closed early because of that competing approval.

What This Doesn't Mean

This must never be described or badged as an FDA-approved use of pembrolizumab — readers should not confuse this drug's AMBASSADOR trial result with nivolumab's separate, already-approved adjuvant indication. Overall survival, the trial's co-primary endpoint, was not yet statistically significant at the reported follow-up and remains an immature endpoint — this record makes no overall-survival claim.

Why It Matters

A second PD-1 inhibitor demonstrating a real disease-free-survival benefit in this adjuvant bladder-cancer setting strengthens the overall evidence base for immunotherapy after bladder-removal surgery, even though this specific drug/indication pairing has not itself been approved.

Promise & Proof

Proof — strength of the evidence 4 / 5
  • Base score from evidence stage: Later-Stage Human.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with high-risk muscle-invasive or locally advanced urothelial (bladder) carcinoma, following radical surgical removal of the bladder (radical cystectomy or nephroureterectomy), randomized to adjuvant pembrolizumab or observation alone. (Adults)

Do not present this as an available, FDA-approved treatment option — as of this review, patients seeking an approved adjuvant PD-1 inhibitor after bladder-removal surgery would be considering nivolumab, a different drug, not pembrolizumab in this specific setting. Overall-survival data remain immature and should be re-checked before this record is revised.

Full evidence details
Study design
Randomized controlled trial
Sample size
702

Funding & Conflicts

Sponsor: National Cancer Institute (NCI), led by the Alliance for Clinical Trials in Oncology, with Merck (pembrolizumab's manufacturer) participating via a Cooperative Research and Development Agreement (CRADA) — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

AMBASSADOR trial finds adjuvant pembrolizumab extends disease-free survival in high-risk bladder cancer — not yet FDA-approved for this use

https://cancerdiscoveries.com/discoveries/ambassador-trial-finds-adjuvant-pembrolizumab-extends-disease-free-survival-in-high-risk-bladder-cancer-not-yet-fda-approved-for-this-use/

Evidence stage: Later-Stage Human

What This Means

In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma. This is a real, positive trial result — but pembrolizumab has NOT been granted FDA approval for this specific adjuvant indication. A different, related PD-1 inhibitor, nivolumab, already holds that FDA approval (since 2021) for a similar adjuvant urothelial-carcinoma setting, and AMBASSADOR's own enrollment was closed early because of that competing approval.

What This Doesn't Mean

This must never be described or badged as an FDA-approved use of pembrolizumab — readers should not confuse this drug's AMBASSADOR trial result with nivolumab's separate, already-approved adjuvant indication. Overall survival, the trial's co-primary endpoint, was not yet statistically significant at the reported follow-up and remains an immature endpoint — this record makes no overall-survival claim.

Why It Matters

A second PD-1 inhibitor demonstrating a real disease-free-survival benefit in this adjuvant bladder-cancer setting strengthens the overall evidence base for immunotherapy after bladder-removal surgery, even though this specific drug/indication pairing has not itself been approved.

Primary sources

  • AMBASSADOR/A031501 trial primary results: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma (NEJM) — https://doi.org/10.1056/NEJMoa2401726 (DOI 10.1056/NEJMoa2401726, PMID 39282902)

Date verified: 2026-08-13

Correction status: No correction or retraction